With An Additional Active Ingredient Patents (Class 514/6.5)
  • Patent number: 10914720
    Abstract: Disclosed herein is a method to evaluate the stability of a protein-based formulation including a protein, a peptide and/or a protein derivative and a buffer relative to a lubricant of a lubricated container in which the formulation is intended to be stored, including: a) Evaluating a decrease over time of interfacial tension between the buffer and the lubricant, b) Evaluating a decrease over time of interfacial tension between the protein-based formulation and the lubricant, c) Identifying at least one component of the protein-based formulation interacting with the lubricant by comparing the decrease evaluated in step b) with the decrease evaluated in step a).
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: February 9, 2021
    Assignee: Becton Dickinson France
    Inventors: Tzvetelina Chevolleau, Jean-Bernard Hamel
  • Patent number: 10851374
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: December 1, 2020
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 10799564
    Abstract: A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: October 13, 2020
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Joseph Chung Tak Wong, Sarah Elizabeth Lee
  • Patent number: 10772879
    Abstract: This invention relates to pharmaceutical formulations comprising 1-(2-thien-2?-yl-2-oxo-ethyl)-3-(methanesulfonyl hydrazine carbonyl) pyridinium, its pharmaceutically acceptable salts, salt-cocrystals and co-crystals, particularly 1-(2-thien-2?-yl-2-oxo-ethyl)-3-5(methanesulfonyl hydrazine carbonyl) pyridinium chloride. The formulations are suitable for oral administration and also comprise a permeability enhancer or a suitable base or a mixture thereof. The formulations of this invention are for treating diseases associated with advanced glycation end products.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: September 15, 2020
    Assignee: Torrent Pharmaceuticals Limited
    Inventors: Chaitanya Dutt, Jaya Abraham, Vivek Mishra, Amit Kesarwani, Ramesh Chandra Gupta, Shailesh Deshpande, Shital Kumar Zambad, Anoop Mathur, Jignesh Kotecha, Sachin Latad, Manish Patel, Anita Chaudhari
  • Patent number: 10596231
    Abstract: The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 24, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Mathias Norrman, Susanne Hostrup, Dorte Bjerre Steensgaard, Holger Martin Strauss, Rosa Rebecca Erritzoee Hansen, Svend Havelund, Morten Schlein, Jesper Soendergaard Pedersen
  • Patent number: 10457716
    Abstract: The instant disclosure provides a microscale method for providing correctly folded, and assembled biologically active proteins in an efficient and shorted time frame, compared to conventional protein production techniques. Proteins produced from inclusion bodies and other aggregated protein sources are provided. Microscale production of correctly folded and assembled class I MHC protein and complexes thereof are also provided for, as well as for high throughput production for use in epitope discovery protocols. Microscale production of complex proteins from protein aggregates and preparations containing protein aggregates is provided that requires less than 24 hours of processing time.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: October 29, 2019
    Assignee: University of Notre Dame du Lac
    Inventors: Brian M Baker, Lance Hellman
  • Patent number: 10279048
    Abstract: The invention encompasses therapeutic formulations comprising a protein active ingredient and a stabilizing excipient, methods of improving stability in a therapeutic formulation comprising a protein active ingredient by adding a stability-improving amount of a stabilizing excipient to the therapeutic formulation, and methods of reducing adverse infusion-related effects in a patient, comprising administering to a patient in need thereof a therapeutic formulation comprising a protein active ingredient and a stabilizing excipient.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 7, 2019
    Assignee: REFORM BIOLOGICS, LLC
    Inventors: David S. Soane, Robert P. Mahoney, Philip Wuthrich, Daniel G. Greene
  • Patent number: 10155000
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Meinicke, Maximilian Von Eynatten
  • Patent number: 10092513
    Abstract: The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: October 9, 2018
    Assignee: SANOFI
    Inventors: Isabel Muhlen-Bartmer, Monika Ziemen
  • Patent number: 9937117
    Abstract: A method of reducing hair loss (alopecia) in a patient undergoing or scheduled to undergo chemotherapy is claimed. The method involves administering brimonidine or a pharmaceutically acceptable salt thereof to the site of the hair follicles.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: April 10, 2018
    Assignee: GALDERMA S.A.
    Inventor: Philippe Andres
  • Patent number: 9872844
    Abstract: Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: January 23, 2018
    Assignee: NuSirt Sciences, Inc.
    Inventors: Michael Zemel, Antje Bruckbauer
  • Patent number: 9795678
    Abstract: A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 24, 2017
    Assignee: ADOCIA
    Inventors: Olivier Soula, Richard Charvet, Bertrand Alluis
  • Patent number: 9730980
    Abstract: Methods for treating type one diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type one diabetes mellitus are disclosed, including combination therapies with insulin. The methods include administering an effective amount of apolipoprotein A-IV to the subject having type I diabetes. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type one diabetes mellitus.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: August 15, 2017
    Assignee: University of Cincinnati
    Inventors: Patrick Tso, Xiaoming Li
  • Patent number: 9604920
    Abstract: The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: March 28, 2017
    Inventor: Mohan Murali Alapati
  • Patent number: 9487783
    Abstract: Described herein are compounds comprising modified oligonucleotides that are complementary to miR-103 and/or miR-107 and methods of treating diseases and disorders using the compounds.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 8, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Balkrishen Bhat, Neil W. Gibson, Diedre MacKenna, Brandee Wagner, David P. Bartel
  • Patent number: 9132171
    Abstract: Methods, compositions, and devices for treating restenosis are described. In accord with the invention, a composition containing CTGF and insulin is applied to blood vessels and restenosis is reduced or prevented.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: September 15, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Shakti Goel, Lian Guo, K. Craig Kent
  • Patent number: 9096535
    Abstract: The present invention pertains to novel enaminoketones containing a CF3O-group, novel pyrazole-derivatives containing a CF3O group as well as to a novel process for their preparation comprising aminoformylation of CF3O-ketones and cyclization of the obtained CF3O-enaminoketones with hydrazines to trifluoromethoxy pyrazoles.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: August 4, 2015
    Assignees: BAYER INTELLECTUAL PROPERTY GMBH, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sergii Pazenok, Bernard Langlois, Thierry Billard, Julien Barbion, Olivier Marrec, Jean-Pierre Vors
  • Publication number: 20150139978
    Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 21, 2015
    Inventors: Ming-Jen Cheng, Ping-Hsun Yang, Ming-Der Wu, Shie-Jea Lin, Gwo-Fang Yuan, Yen-Lin Chen, Hsuen-Chun Liao, Kai-Ping Chen
  • Publication number: 20150133371
    Abstract: The present invention relates to a method or composition for glycemic control in a subject, which is effective for treating diabetes mellitus, comprising administering the subject with a pharmaceutical composition comprising a therapeutically effective amount of an aliphatic alcohol having a general formula of CH3(CH2)nCH2OH, wherein n is an integer from 10 to 40, such as tetracosanol, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 12, 2013
    Publication date: May 14, 2015
    Applicant: National Dong Hwa University
    Inventors: Ching-Feng Weng, Chin-piao Chen, Yi-Chen Chia, Chia-Yu Hsu
  • Publication number: 20150133372
    Abstract: Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 14, 2015
    Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventor: Laurence M. Katz
  • Publication number: 20150112302
    Abstract: Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.
    Type: Application
    Filed: October 13, 2014
    Publication date: April 23, 2015
    Inventors: Sarnath Chattaraj, Kiem H. Dang, Hsi Chung Fusselman, Poonam S. Gulati, Lance P. Hoffman, Guangping Zhang
  • Patent number: 9006177
    Abstract: The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: April 14, 2015
    Assignee: Advinus Therapeutics Limited
    Inventors: Dinesh Barawkar, Sujay Basu, Vidya Ramdas, Minakshi Naykodi, Meena Patel, Yogesh Shejul, Sachin Thorat, Anil Panmand
  • Publication number: 20150099696
    Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed to compounds suitable for the treatment of Disease conditions such as hyperlipidemia.
    Type: Application
    Filed: June 26, 2012
    Publication date: April 9, 2015
    Applicant: Cadila Healthcare Limited
    Inventors: Harikishore Pingali, Pankaj Makadia, Vrajesh Pandya, Sairam V.V.M. Kalapatapu
  • Publication number: 20150094259
    Abstract: A transdermal delivery device in the form of a transdermal delivery patch for the delivery of insulin is disclosed. The patch comprises cross-linked amidated low methoxy pectin, insulin and a transdermal transfer enhancing agent.
    Type: Application
    Filed: March 7, 2013
    Publication date: April 2, 2015
    Applicant: University Of Kwazulu-Natal
    Inventors: Cephas Musabayane, Fanie Retief Van Heerden, Samson Mukaratirwa, Mark Andrew Tufts
  • Publication number: 20150094260
    Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.
    Type: Application
    Filed: August 14, 2014
    Publication date: April 2, 2015
    Inventors: Liora BRAIMAN-WIKSMAN, Yuval Sagiv, Ofra Levy-Hacham, Tamar Tennenbaum
  • Patent number: 8993516
    Abstract: A method treating a patient includes administering a physiologically effective amount of a fibrillation-resistant insulin analogue or a physiologically acceptable salt thereof to the patient. The fibrillation-resistant insulin analogue or a physiologically acceptable salt thereof, contains an insulin A-chain sequence modified at position A8 and an insulin B-chain sequence or an analogue thereof. The fibrillation-resistant insulin analogue may exhibit thermodynamic stability similar to or exceeding that of wild-type human insulin and displays a susceptibility to fibrillation similar to or exceeding that of wild-type human insulin. An insulin analogue may display greater in vitro insulin receptor binding than normal insulin while displaying binding to IGFR less than twice that of normal insulin and less than that of fast-acting insulin analogs.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: March 31, 2015
    Assignee: Case Western Reserve University
    Inventor: Michael Weiss
  • Publication number: 20150087586
    Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise conjugated C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.
    Type: Application
    Filed: March 25, 2013
    Publication date: March 26, 2015
    Inventors: Sheri Barrack, James Callaway, Michelle Mazzoni
  • Publication number: 20150086616
    Abstract: Oral non-steroidal anti inflammatory drugs (NSAIDs) are not an effective treatment of Alzheimer's disease, because the brain dose is too low. Nasal delivery of NSAIDs such as ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen, which inhibit the enzymes cyclooxygenase-1 (cox-1) and cox-2, are used to prevent and/or treat Alzheimer's disease, a low grade brain inflammation. The large amount of nasal NSAIDs (e.g., ibuprofen, flurbiprofen, indomethacin, diclofenac, or naproxen) that reaches the brain far exceeds that from an oral dose. Low-molecular-weight lipophilic drugs, such as ibuprofen, naproxen, indomethacin, diclofenac, and flurbiprofen, are readily absorbed into the brain by the intranasal route. Alzheimer's starts in the entorhinal cortex, which is closely connected to the olfactory nerves, and spreads anatomically in a defined pattern. Therefore, a nasal NSAID would readily reach the region of the brain where it acts therapeutically.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 26, 2015
    Inventor: Steven Lehrer
  • Patent number: 8987199
    Abstract: In one embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. In yet another embodiment of the invention, a pharmaceutical composition for intranasal administration comprises insulin, clioquinol, dimethyl sulfoxide and at least one pharmaceutically acceptable excipient. The pharmaceutical compositions of the invention may be used to treat or prevent a neurodegenerative disorder such as Alzheimer's disease, stroke, Parkinson's disease, multiple sclerosis, spinal cord injuries, and/or traumatic brain injuries and the like, in addition to other systemic and local diseases.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: March 24, 2015
    Assignee: Nerve Access, Inc.
    Inventors: Yaser A. Abdel Maksoud, Mustafa A. Maher
  • Patent number: 8987198
    Abstract: Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 24, 2015
    Assignees: The Administrators of the Tulane Educational Fund, The United States Department of Agriculture, Wake Forest University Health Sciences, Nume Health, LLC
    Inventors: Matthew E. Burow, Stephen M. Boue, Thomas T. Y. Wang, Deepak Bhatnagar, Charles E. Wood, Mark L. Helman
  • Publication number: 20150079055
    Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
    Type: Application
    Filed: September 23, 2014
    Publication date: March 19, 2015
    Applicants: Children's Hospital Medical Center, The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 8980828
    Abstract: The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: March 17, 2015
    Assignee: Poxel S.A.S.
    Inventors: Didier Mesangeau, Daniel Cravo, Annick Audet
  • Patent number: 8980829
    Abstract: Disclosed are an aryl glycoside compound as represented by formula I or formula I?, a pharmaceutically acceptable salt thereof, optical isomer thereof or a prodrug thereof. The present invention relates to a method of preparing said aryl glycoside compound and the use thereof. The aryl glycoside compound of the present invention has an excellent ability on inhibit SGLT activity, especially SGLT2 activity, and is diabetes-fighting medicine with great potential.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: March 17, 2015
    Assignees: Shanghai Yingli Science and Technology Co., Ltd, Shanghai Chempartner Co., Ltd
    Inventors: Zusheng Xu, Su Qian
  • Publication number: 20150065423
    Abstract: A rapid acting injectable formulation is provided comprising a therapeutic peptide and a vasodilatory agent. The therapeutic peptide has a molecular weight of greater than about 500 Daltons, and the vasodilatory agent is present in an amount effective to increase the absorption of the therapeutic peptide. A method of increasing absorption of a therapeutic peptide by using such a formulation is also provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Bryan E. Laulicht, Sasha H. Bakhru, Solomon S. Steiner
  • Patent number: 8969291
    Abstract: The present invention is directed to methods for modulating the Th1 /Th2 cell balance toward anti-inflammatory cytokine producing cells in a subject comprising decreasing the amount, the expression, or the activity of leptin in a subject sufficient to modulate the Th1 /Th2 cell balance toward anti-inflammatory cytokine producing cells. The invention is also directed to methods of treatment of an immune-related disorder in a subject comprising decreasing the amount, the expression, or the activity of leptin in the subject sufficient to treat the immune-related disorder.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: March 3, 2015
    Assignee: Enzo Therapeutics, Inc.
    Inventors: Yaron Ilan, Eran Elinav
  • Patent number: 8968716
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: March 3, 2015
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Patent number: 8969297
    Abstract: Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: March 3, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventor: Laurence M. Katz
  • Publication number: 20150056167
    Abstract: Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, andor lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
    Type: Application
    Filed: September 4, 2014
    Publication date: February 26, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Publication number: 20150057220
    Abstract: Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.
    Type: Application
    Filed: April 16, 2013
    Publication date: February 26, 2015
    Inventors: Michel Therien, Yves Leblanc, Yongxin Han
  • Patent number: 8962636
    Abstract: The present invention relates to substituted quinazolines of formula (I) wherein X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures and salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV(DPP-IV).
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 24, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Waldemar Pfrengle, Markus Frank, Thomas Klein
  • Publication number: 20150051143
    Abstract: The disclosure provides for a method for treating a fatty liver disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic, or has normal or substantially normal biliary tract function; and administering a therapeutically effective amount of a pharmaceutical composition comprising ethyl eicosapentanoate (EPA-E). In some cases EPA-E present may be at least 40% by weight in total of the fatty acids and their derivatives.
    Type: Application
    Filed: March 13, 2014
    Publication date: February 19, 2015
    Applicant: Mochida Pharmaceutical Co., LTD
    Inventors: Tsuyoshi Harada, Hideo Kanehiro, Kiyoshi Mizuguchi
  • Publication number: 20150051144
    Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as hyperlipidemia and also have a beneficial effect on cholesterol.
    Type: Application
    Filed: September 26, 2012
    Publication date: February 19, 2015
    Inventors: Harikishore Pingali, Vrajesh Pandya
  • Publication number: 20150051145
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 19, 2015
    Applicant: Genfit
    Inventors: Raphael DARTEIL, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Publication number: 20150024995
    Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
    Type: Application
    Filed: October 3, 2014
    Publication date: January 22, 2015
    Inventor: Anthony H. Cincotta
  • Patent number: 8937042
    Abstract: Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: January 20, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Anne Plum, Dorte Bjerre Steensgaard, Jens Kaalby Thomsen, Morten Schlein, Anne Sofie Kajær Markussen, Christian Poulsen
  • Publication number: 20150017238
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 15, 2015
    Applicant: Oramed, Ltd.
    Inventor: Miriam Kidron
  • Patent number: 8933024
    Abstract: The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: January 13, 2015
    Assignee: Sanofi
    Inventors: Stefan Petry, Norbert Tennagels, Karl-Heinz Baringhaus
  • Publication number: 20150010494
    Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Publication number: 20150010508
    Abstract: The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Claresa S. Levetan, Loraine V. Upham
  • Patent number: RE45610
    Abstract: The invention relates to peptides of general formula (I): that can reduce or remove bags formed under the eyes, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or dermopharmaceutically acceptable salts thereof, wherein X is cystenyl, seryl, threonyl or aminobutyryl; R1 is H or alkyl, aryl, aralkyl or acyl group; and R2 is amino, hydroxy or thiol, all of them substituted or non-substituted with aliphatic or cyclic groups. The invention also relates to a method of obtaining, cosmetic or dermopharmaceutical compositions containing them and their use for treating skin, preferably for reducing or removing bags formed under the eyes.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 14, 2015
    Assignee: LIPOTEC, S.A.
    Inventors: Arturo Puig Montiel, Juan Cebrían Puche, Elena Passerini